Tipsheet
What matters at India’s listed companies
Earnings · Medical Equipment · Micro cap

Transpact's revenue doubled to ₹18 lakh. The profit, too.

Full-year revenue jumped to ₹18 lakh from ₹8.25 lakh, with net profit surging to ₹8.64 lakh. The absolute numbers remain minuscule.


Mkt cap₹7.35 cr
P/E84.46×
ROE1.99%
Debt / eq.0.22
₹18.00 lakh FY26 full-year revenue, up from ₹8.25 lakh.

What's new

  • Audited FY26 results show revenue doubled to ₹18.00 lakh and net profit surged to ₹8.64 lakh from ₹0.90 lakh.
  • The growth was driven by higher operational activity, per managing director Raman Talwar.
  • Statutory auditor gave an unmodified, clean opinion on the financial statements.

Why this matters

The percentage growth is eye-catching, but the base is tiny. This is a nano-cap with an ₹8 crore market cap reporting results in single-digit lakhs. The clean audit opinion removes a procedural risk, but the scale of the business is the real story here.

What we're watching

  • Whether the operational uptick can be sustained or is a one-off step-change.
  • Any follow-on announcements on new business or capacity.
  • The stock's liquidity at these absolute-value levels.

The full read

Transpact Enterprises' FY26 results show revenue doubling to ₹18.00 lakh and net profit jumping to ₹8.64 lakh from a base of ₹0.90 lakh. The percentage moves are dramatic. The underlying reality is a business with annual sales of eighteen lakh rupees and a market capitalisation of ₹8 crore. Managing director Raman Talwar cited higher operational activity as the driver. The statutory auditor's unmodified opinion is a procedural green light. For a company this size, the results are a data point, not a trend. The question isn't whether growth was strong, but whether it's visible at scale.

Questions answered

How big is this company's business really?
Transpact's full-year revenue is ₹18 lakh, which is approximately 2.25% of its ₹8 crore market capitalisation. The business is minuscule even for a nano-cap.
What drove the improvement?
Managing director Raman Talwar attributed the growth to 'higher operational activity,' without providing further detail in the results filing.
Were there any concerns from the auditor?
No. The statutory auditor issued a clean, unmodified opinion on the audited standalone financial statements for both the half-year and full year.
Is the profit growth sustainable?
The filing provides no guidance or forward commentary. It is a standard statutory disclosure of past results, leaving the sustainability of the improvement as an open question.
Mentioned: Transpact Enterprises Ltd · Raman Talwar · ₹18.00 lakh FY26 revenue
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Transpact Enterprises Ltd.

Pharmaceuticals
₹7 cr
P/E 83.79×

Latest quarter · Mar 2026

Sales₹0 cr
Net profit₹0 cr
Op. margin+58.8%
EPS₹0.96

Strength & growth

Debt / equity0.22×
Current ratio2.49×